Abstract
Objective
To assess the stabilities of Arg-Gly-Asp-Trp-Arg (RGDWR, designated as RWR), a new patented antithrombotic small peptide, and its derivative with ω-aminocaprylic acid on its N-terminus (ωRWR).
Results
RWR in rat plasma was decreased by between 32 and 48% after 4 h incubation on ice, indicating its instability in plasma. In contrast, ωRWR in plasma remained at 96–107%. Concentration changes were within 6.2% for ωRWR after storage in various conditions. ωRWR is therefore stable in rat plasma, as well as under different storage methods. Furthermore, ω-aminocaprylic acid added onto the RWR peptide did not affect its antiplatelet aggregation activity.
Conclusions
A novel small peptide, ωRWR, has been developed with a good stability for possible antithrombotic use.
Similar content being viewed by others
References
Amin M, Mansourian M, Koning GA, Badiee A, Jaafari MR, ten Hagen TL (2015) Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. J Control Rel 220:308–315
Assumpcao TC, Ribeiro JM, Francischetti IM (2012) Disintegrins from hematophagous sources. Toxins 4:296–322
Blue R, Kowalska MA, Hirsch J, Murcia M, Janczak CA, Harrington A, Jirouskova M, Li J, Fuentes R, Thornton MA, Filizola M, Poncz M, Coller BS (2009) Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist. Blood 114:195–201
Bol’shakov OI, Akala EO (2014) MS-monitored conjugation of poly(ethylene glycol) monomethacrylate to RGD peptides. J Appl Polym Sci Symp 131:40385
Chen H, Niu G, Wu H, Chen X (2016) Clinical application of radiolabeled RGD peptides for PET imaging of integrin alphavbeta3. Theranostics 6:78–92
Cho J, Mosher DF (2006) Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi. Blood 107:3555–3563
Cui W, Di X (2015) Clinical application of new antithrombotic drugs. Chin J Cardio Med 20:328–333
Durkan K, Jiang Z, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, Szczodroski AF, Liu L, Miao Y, Reynolds TS, Smith CJ (2014) A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] alphavbeta3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl Med Biol 41:133–139
Feng C, Li X, Dong C, Zhang X, Zhang X, Gao Y (2015) RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer. Drug Des Devel Ther 9:4613–4620
Hagemeyer CE, Peter K (2010) Targeting the platelet integrin GPIIb/IIIa. Curr Pharm Des 16:4119–4133
Hoekman JD, Srivastava P, Ho RJ (2014) Aerosol-stable peptide-coated liposome nanoparticles: a proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure. J Pharm Sci 103:2231–2239
Lamande-Langle S, Collet C, Hensienne R, Vala C, Chretien F, Chapleur Y, Mohamadi A, Lacolley P, Regnault V (2014) ‘Click’ glycosylation of peptides through cysteine propargylation and CuAAC. Bioorg Med Chem 22:6672–6683
Lei Y, Wang J, Xie C, Wagner E, Lu W, Li Y, Wei X, Dong J, Liu M (2013) Glutathione-sensitive RGD-poly(ethylene glycol)-SS-polyethylenimine for intracranial glioblastoma targeted gene delivery. J Gene Med 15:291–305
Maschauer S, Haubner R, Kuwert T, Prante O (2014) (18)F-glyco-RGD peptides for PET imaging of integrin expression: efficient radiosynthesis by click chemistry and modulation of biodistribution by glycosylation. Mol Pharm 11:505–515
Meyer dos Santos S, Kuczka K, Picard-Willems B, Nelson K, Klinkhardt U, Harder S (2015) The integrin antagonist, cilengitide, is a weak inhibitor of alphaIIbbeta3 mediated platelet activation and inhibits platelet adhesion under flow. Platelets 26:59–66
O’Connor A, Marsat JN, Mitrugno A, Flahive T, Moran N, Brayden D, Devocelle M (2014) Poly(Ethylene glycol)-based backbones with high peptide loading capacities. Molecules 19:17559–17577
Rutherfurd KJ, Gill HS (2000) Peptides affecting coagulation. Br J Nutr 84(Suppl 1):S99–102
Ungerer M, Munch G (2013) Novel antiplatelet drugs in clinical development. Thromb Haemost 110:868–875
Wang Y, Zhao Y, Sun R, Kong W, Wang B, Yang G, Li Y (2015) Discovery of novel antagonists of glycoprotein IIb/IIIa-mediated platelet aggregation through virtual screening. Bioorg Med Chem Lett 25:1249–1253
Yang T, Niu B, Cheng NL (2009) Replacement of RGD motif with RGDNM attenuates echistatin’s anti-platelet aggregation effect, but enhances its inhibition on angiogenesis. Chin J Biochem Mol Biol 25:834–838
Yang L-J, Niu B, Zhang D, Yang T (2015) Substitution of the Echistatin amino acid motif RGDD with KGDW enhances inhibition of platelet aggregation and thrombogenesis. Int J Pept Res Ther 21:451–458
Zhang J, Mujeeb A, Du Y, Lin J, Ge Z (2015) Probing cell-matrix interactions in RGD-decorated macroporous poly (ethylene glycol) hydrogels for 3D chondrocyte culture. Biomed Mater 10:035016
Zhao H, Yang T, Yang L (2013) The impact of receptor action of RWR by integrin αIIbβ3 on platelet surface on thrombosis. Chin J Biol 26:1126–1129
Zhen Z, Tang W, Chen H, Lin X, Todd T, Wang G, Cowger T, Chen X, Xie J (2013) RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano 7:4830–4837
Zheng H, Zhao H, Wang SH (2015) Experimental study of toxicology of antithrombotic small peptides RWR. Chin J Biochem Pharm 35:6–10
Acknowledgements
We appreciate Prof. Gongqin Sun from the University of Rhode Island for carefully proofreading the manuscript during revision. This study was supported by the National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Twelfth Five-year Plan Period (2012ZX09103301-010), the Youth Fund of National Natural Science Fund (81101895), the Research Project Supported by Shanxi Scholarship Council of China (2016-050), and the Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province (2014-179).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
All authors declare that they have no conflict of interests.
Ethical approval
All animal procedures were approved by the Animal Care and Scientific Committee of Shanxi Medical University.
Informed consent
Not Applicable.
Rights and permissions
About this article
Cite this article
Yang, L., Zhang, L., Yan, L. et al. Stability assessment of a new antithrombotic small peptide, Arg-Gly-Asp-Trp-Arg (RGDWR), and its derivative. Biotechnol Lett 39, 1183–1190 (2017). https://doi.org/10.1007/s10529-017-2346-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10529-017-2346-x